High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group

Thielen, N.; Holt, B. van der; Verhoef, G.E.G.; Ammerlaan, R.A.H.M.; Sonneveld, P.; Janssen, J.J.W.M.; ... ; Cornelissen, J.J. (2013)

Article / Letter to editor

• Chronic myeloid leukemia
• Imatinib
• Cytarabine
• Major molecular response

• All authors: Thielen, N.; Holt, B. van der; Verhoef, G.E.G.; Ammerlaan, R.A.H.M.; Sonneveld, P.; Janssen, J.J.W.M.; Deenik, W.; Falkenburg, J.H.F.; Kersten, M.J.; Sinnige, H.A.M.; Schipperus, M.; Schattenberg, A.; Kooy, R.V.; Smit, W.M.; Chu, I.W.T.; Valk, P.J.M.; Ossenkoppele, G.J.; Cornelissen, J.J.
• Date: 2013-08-31
• Journal: Annals of Hematology
• Volume: 92
• Issue: 8
• Pages: 1049 - 1056
• DOI: doi:10.1007/s00277-013-1730-4